期刊文献+

5α还原酶Ⅲ型的生物学特性及其相关研究进展 被引量:4

Biological characteristics of 5α-reductase type 3 and related research progress
原文传递
导出
摘要 5α还原酶(5α-R)已被认为广泛地存在于人类和其他动物体内,对5α-RⅠ型(5α-R1)及5α-RⅡ型(5α-R2)的研究表明,它主要将睾酮、孕酮、醛固酮和去氧皮质酮转化成各自的5α肾上腺酮二氢衍生物,进一步转化为活跃的有明显生理功能的神经类固醇激素。目前对5α-RⅢ型(5α-R3)的研究引起广泛关注。5α-R3分布和表达于人类的小脑、视网膜、心脏、皮肤、肾、前列腺、肝、骨、肌肉、子宫肌层和胰腺。尽管表达水平不同,但研究发现其生理及功能不尽相同,对人类智力障碍和视觉障碍的影响已得到证实。5α-R3的发现将为与其相关疾病的发生和发展,如良性前列腺增生(BPH)、前列腺癌、男性雄激素性脱发(AGA)的研究提供了更为广阔的思路和选择。 5α-reductases (5α-R) are a family of isozymes expressed in a wide host of tissues including humans and animals. The studies of 5α-reductase type 1 (5α-R1) and 5α-reductase type 2 (5α-R2) showed that they con- verted testosterone, progesterone, aldosterone and deoxyeorticosterone into their respective 5α-dihydro-derivatives, which were subsequently transformed into a subclass of neuro-active steroid hormones with distinct physio- logical function. The recent studies confirmed that the expression and tissue distribution of 5α-reductase type 3 (5α-Rα) encompassed the hippocampus and cerebellum of human brain, retina, heart, skin, kidney, prostate, liv- er, skeleton, muscle, myometrium, and pancreas. Furthermore, it has been proved the varying degrees of expression levels had different physiological function and evolvement. For instance, patients with 5α-reductases deficiency exhibit mental retardation and visual impairment. The target of 5α-R3 provides a wide strategy and prosperity in the occurrence and development of associative diseases, such as BPH, prostate cancer and androgenetic alopecia (AGA).
出处 《临床泌尿外科杂志》 2015年第1期79-83,共5页 Journal of Clinical Urology
关键词 5α还原酶Ⅲ型 前列腺增生 前列腺癌 5Α还原酶抑制剂 5α-reductase type 3 benign prostatic hyperplasial prostate cancer 5α-reductase inhibition
  • 相关文献

参考文献31

  • 1Dubrovsky B.Neurosteroids,neuroactive steroids,and symptoms of affective disorders[J].Pharmacol Biochem Behav,2006,84(4):644-655.
  • 2Uemura M,Tamura K,Chung S,et al.Novel 5alphasteroid reductase(SRD5A3,type-3)is overexpressed in hormone-refractory prostate cancer[J].Cancer Sci,2008,99(1):81-86.
  • 3Cantagrel V,Lefeber D J,Ng B G,et al.SRD5A3is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder[J].Cell,2010,142(2):203-217.
  • 4Godoy A,Kawinski E,Li Y,et al.5α-reductase type 3 expression in human benign and malignant tissues:a comparative analysis during prostate cancer progression[J].Prostate,2011,71(10):1033-1046.
  • 5Morava E,Wevers R A,Cantagrel V,et al.A novel cerebello-ocular syndrome with abnormal glycosylation due to abnormalities in dolichol metabolism[J].Brain,2010,133(11):3210-3220.
  • 6Mawhinney M,Mariotti A.Physiology,pathology and pharmacology of the male reproductive system[J].Periodontol 2000,2013,61(1):232-251.
  • 7Maimoun L,Philibert P,Cammas B,et al.Phenotypical,biological,and molecular heterogeneity of 5α-reductase deficiency:an extensive international experience of 55patients[J].J Clin Endocrinol Metab,2011,96(2):296-307.
  • 8Kasapkara C S,Tümer L,EzgüF S,et al.SRD5A3-CDG:apatient with a novel mutation[J].Eur J Paediatr Neurol,2012,16(5):554-556.
  • 9Gründahl J E,Guan Z,Rust S,et al.Life with too much polyprenol:polyprenol reductase deficiency[J].Mol Genet Metab,2012,105(4):642-651.
  • 10Morrow A L.Recent developments in the significance and therapeutic relevance of neuroactive steroids--Introduction to the special issue[J].Pharmacol Ther,2007,116(1):1-6.

同被引文献33

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部